(EMAILWIRE.COM, June 02, 2008 ) Denver, CO - LegalView, the number one site for everything legal on the Internet, recently used its mesothelioma blog to report on a new potential mesothelioma cancer treatment after a study was released explaining the use of non-steroidal anti-inflammatory drugs (NSAIDs), in combination with cisplatin (CDDP), causes significant anti-tumoral activity on mesothelioma cells. The study, released in the Journal of Translational Medicine introduced the new findings regarding the potential treatment for a variety of human cancers especially mesothelioma (http://mesothelioma.legalview.com).
Mesothelioma is a deadly form of cancer that is highly preventable if the appropriate precautions are taken. The cause of mesothelioma is related to the inhalation of asbestos fibers and asbestos dust, which was heavily used in insulation for buildings and ships during the 20th century. Asbestos is derived from vermiculite, a mineral mined throughout the United States until it was eventually linked to mesothelioma. Thousands of individuals were likely exposed to asbestos through contact, which may have included work in vermiculite mines, construction of homes or apartment buildings where asbestos-tainted insulation was used, or through work at shipyards. It takes years for mesothelioma cancer to develop after initial exposure to asbestos, which is why individuals often do not know they are suffering from mesothelioma until it is too late. Those who have been diagnosed with mesothelioma should speak with an experienced mesothelioma lawyer (http://mesothelioma.legalview.com/find-mesothelioma-lawer.aspx) regarding the development of a mesothelioma lawsuit (http://mesothelioma.legalview.com/mesothelioma-lawsuit-results.aspx) that may provide monetary compensation for pain and suffering as well as the high costs of medical bills often associated with a mesothelioma diagnosis (http://mesothelioma.legalview.com). For more information, visit the mesothelioma blog at http://mesothelioma.legalview.com/blog/.
Also, peruse the hundreds of legal issues found at the LegalView homepage and learn the latest on the prescription drug Vytorin controversy or the Chantix and Singulair side effects. Used to treat high cholesterol and lipid buildup in arteries, Vytorin is often used in combination with a similar drug known as Zetia. However, a report that was released detailing the costs and potential benefits of the Vytorin treatments (http://vytorin.legalview.com) discovered that the drug was less effective than similar generic versions and cost nearly three times the amount of generic versions as well. Although the drug has not been recalled, a class action lawsuit has been mounted against the drug's manufacturers.
Chantix, a smoking cessation aid, has been linked to serious side effects that include suicide and depression as well as erratic behavior among patients. Nearly 400 patient reports flooded the U.S. Food and Drug Administration (FDA) offices in late 2007 consisting of these severe Chantix side effects (http://chantix.legalview.com) and complications. Similar to the Chantix side effects are the Singulair risks (http://singulair.legalview.com), which mirror the complications of the Chantix prescription drug side effects. While Singulair is used to treat allergy and asthma among patients, in early 2008, patients began to report of an increased link between Singulair treatments and depression, moodiness and suicidal thoughts and actions. Patients of all ages, including children, were reportedly affected by the Singulair risks.
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: